0004

Pacific Shuanglin Bio-Pharmacy Co., Ltd. (000403)

Market Closed
11 Jul, 06:57
XSHE XSHE
¥
17. 84
+0.08
+0.45%
¥
17.06B Market Cap
- P/E Ratio
0.8% Div Yield
8,616,707 Volume
- Eps
¥ 17.76
Previous Close
Day Range
17.68 17.96
Year Range
16.75 28.8
Want to track 000403 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

000403 closed Friday higher at ¥17.84, an increase of 0.45% from Thursday's close, completing a monthly decrease of -1.33% or ¥0.24. Over the past 12 months, 000403 stock lost -15.57%.
000403 is not paying dividends to its shareholders.
The last earnings report, released on May 21, 2025, missed the consensus estimates by -0.16%. On average, the company has surpassed earnings expectations by 0.1%, based on the last three reports.
Pacific Shuanglin Bio-Pharmacy Co., Ltd. has completed 2 stock splits, with the recent split occurring on Jun 04, 2025.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on XSHE (CNY).

000403 Chart

Pacific Shuanglin Bio-Pharmacy Co., Ltd. (000403) FAQ

What is the stock price today?

The current price is ¥17.84.

On which exchange is it traded?

Pacific Shuanglin Bio-Pharmacy Co., Ltd. is listed on XSHE.

What is its stock symbol?

The ticker symbol is 000403.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.8%.

What is its market cap?

As of today, the market cap is 17.06B.

Has Pacific Shuanglin Bio-Pharmacy Co., Ltd. ever had a stock split?

Pacific Shuanglin Bio-Pharmacy Co., Ltd. had 2 splits and the recent split was on Jun 04, 2025.

Pacific Shuanglin Bio-Pharmacy Co., Ltd. Profile

Biotechnology Industry
Healthcare Sector
Mr. Xiankui Rong CEO
XSHE Exchange
CNE000000F14 ISIN
CN Country
2,635 Employees
- Last Dividend
4 Jun 2025 Last Split
7 Jun 1996 IPO Date

Overview

Pacific Shuanglin Bio-pharmacy Co., Ltd., previously known as Southern Shuanglin Bio-pharmacy Co., Ltd., is a significant figure in China's biomedical sector, focusing on the research, development, production, and sales of blood products. Its foundation was laid in 1993, and in April 2021, it underwent a name change to reflect its broadened outlook and commitments. Based in Taiyuan, China, Pacific Shuanglin Bio-pharmacy Co., Ltd. not only concentrates on blood product manufacturing but also actively participates in the investment, consultation, and technological advancement of pharmaceutical and biotechnological development projects. Additionally, it offers electronic product information consultation, underlining its versatile approach to serving the healthcare and biopharmaceutical industries.

Products and Services

  • Human Serum Albumin - This crucial product is widely used for treating and managing conditions like burns, shock, and low protein levels due to surgery or liver failure.
  • Human Immunoglobulin - Vital for immune system support, human immunoglobulin is used in the treatment of various immune deficiencies and autoimmune disorders.
  • Intravenous Human Immunoglobulin (PH4) - A specific formulation of human immunoglobulin designed for intravenous administration, making it crucial for treating conditions requiring rapid immune support.
  • Hepatitis B Human Immunoglobulin - Aimed at preventing hepatitis B infection in situations of potential exposure and in patients requiring liver transplantation due to HBV-related liver failure.
  • Tetanus Human Immunoglobulin - Provides passive immunity to tetanus as part of emergency treatment following injuries that may lead to tetanus infection.
  • Rabies Patient Immunoglobulin - Administered as part of post-exposure prophylaxis to prevent the onset of rabies in individuals exposed to potentially rabid animals.
  • Human Coagulation Factor - Essential for the management and treatment of bleeding disorders such as hemophilia, helping in the clotting process.

In addition to these leading products, Pacific Shuanglin Bio-pharmacy Co., Ltd. engages in the broader sphere of the pharmaceutical and biotechnological industry by participating in investment, consultation, and technology promotion projects. This holistic approach towards its business endeavors not only strengthens their product portfolio but also enhances their capabilities in providing comprehensive solutions in the biopharmaceutical domain, including electronic product information consultation services.

Contact Information

Address: Sunshine City Global Financial Center, Taiyuan, China, 030000
Phone: 86 75 9293 1218